[Effect on bone structure and strength by novel anti-osteoporotic agents].
Recent progress in understanding molecular processes underlying osteoporosis has resulted in the development of several new anti-osteoporotic agents that are currently being explored in clinical trials. Denosumab, a monoclonal antibody directed against RANKL, has just approved in Japan and some additional new therapies are lining up for clinical approval in the coming years. Potential agents include cathepsin K inhibitor and sclerostin. Here, I will provide a short overview on these three agents focusing on their effect on structural properties and bone strength.